Open AccessThe Effect of Moderate- and High-Fat Meals on the Bioavailability of Dolutegravir/Rilpivirine Fixed-Dose Combination Tablet
Author(s) -
Rashmi Mehta,
Joseph Piscitelli,
Allen Wolstenholme,
Caifeng Fu,
Herta Crauwels,
Brian Wynne,
Kimberly K. Adkison
Publication year - 2020
Publication title -
clinical pharmacology
Language(s) - English
Resource type - Journals
ISSN - 1179-1438
DOI - 10.2147/cpaa.s250751
Subject(s) - rilpivirine , dolutegravir , bioavailability , pharmacology , meal , fixed dose combination , pharmacokinetics , human immunodeficiency virus (hiv) , chemistry , medicine , food science , virology , antiretroviral therapy , viral load
Dolutegravir 50 mg (DTG) and rilpivirine 25 mg (RPV) are a newly approved 2-drug regimen for the treatment of HIV in virally suppressed patients. A 2-part study evaluated the relative bioavailability and food effect of five experimental fixed-dose combination (FDC) tablet formulations of DTG/RPV. When given with a moderate- or high-fat meal, the absorption of both DTG and RPV was increased, resulting in higher exposures. As per product labelling, DTG/RPV FDC should be taken with a meal.